Back to search

National and Kapodistrian University of Athens

Επιδημιολογική, κλινική, ανοσολογική, αιματολογική, θεραπευτική μελέτη Ελλήνων ασθενών με HIV-1 λοίμωξη

Abstract

dc:description

Anemia is the most common hematologic abnormality, observed in patients with HIV-1 and AIDS, which may have serious implications that vary from functional and quality-of-life decrements to an accelerating progression of the disease and increased risk of death. Several mechanisms are related to anemia, and in a previous retrospective study, composed in the Pathophysiology Department, it has been suggested, that circulating autoantibodies to endogenous erythropoietin (anti-Epo), who were present in a substantial percentage (23.4%) of patients with HIV-1 infection, are an independent predictor of anemia. The above mentioned study due to its retrospective design did not elucidate whether anti-Epo autoantibodies preceded the development of anemia or were simply a concomitant marker of the disease process. The first part of this MD thesis was designed in order to elucidate the above mentioned question. The longitudinal cohort study which was undertaken, consisted of HIV-1 infected patients, who were consecutively screened for the presence of circulating anti-Epo antibodies at the Infectious Disease Unit of the Athens Laikon Hospital. Blood samples were obtained at each patient visit for flow cytometric measurements of CD4+ T lymphocytes, viral load, and other laboratory studies. Erythropoietin serum levels were measured by radioimmunobloting assay, while the anti-Epo were detected by an ELISA assay developed in the laboratory of Pathophysiology Department. The study population consisted of 113 HIV seropositive patients (96 male and 17 female) with mean age ± SD 33.8 ± 12.7 years. Anti-Epo antibodies were detected in 46 (41%) of the patients. Out of 27 patients with anemia 19 (70%) had anti-Epo antibodies as compared with 27 (31%) of 86 patients without anemia (odds ratio [OR], 5.19; 95% confidence interval [CI], 2.02 to 13.3). Epo levels were significantly higher among patients with anemia [median (interquartile range) was 31.3 (40.1) vs 19.4 (13.7) IU/ml, p=0.006], compared to patients without anemia. In univariable analysis the presence of anemia was positively associated with a variety of clinicolaboratory parameters, anti-Epo antibodies included, whilst in multivariable logistic regression analysis, after adjusting for confounders, only anti-Epo antibodies were significantly associated with the presence of anemia (odds ratio [OR], 5.07; 95% confidence interval [CI], 1.25 to 20.49). The patients had a mean ± SD follow up of 105 months ± 40 months, for a total of 2190 visits (average 19.4 visits/patient, range 2-36). Anti-Epo activity and Epo concentrations were measured on 1094 and 1024 visits respectively. Anti-Epo antibodies were associated with higher serum Epo for all visits [45.7 ± 60.4 vs. 31.8 ± 31.7 IU/ml, p<0.001]. On multivariable GEE (generalized estimated equations) analysis, the presence of anti-Epo antibodies, after adjustment for other independent covariates, revealed that anti-Epo positive individuals were twice more likely to become anemic than their seronegative counterparts. Anti-Epo antibodies prevalence declined from 41% (46/113) at enrollment to 29.3% (320/1094) for all visits, in parallel with the prevalence of anemia which dropped from 24% at presentation to 12.8% (279/2184 visits) for all visits, as HAART therapy was increasingly implemented. In fact, anti-Epo prevalence was inversely associated with the severity of immunosuppression reflected by the CD4 count and the use of HAART therapy. In conclusion, the previous study’s data were confirmed and furthermore it is demonstrated that antibodies to endogenous Epo are a strong predictor of anemia in HIV-1 infected patients. HAART reduces the prevalence of both anemia and anti-Epo antibodies. Correlation of the autoantibodies with anemia was confirmed but their role remained obscure, due to the inability of clarifying whether their presence is instrumental for the pathogenesis of anemia or exist as an epiphenomenon along with other circulating autoantibodies in HIV-1 infection, which have no clinical significance and appear as a result of the persistent activation of the immune system. This finding lead to the design of the second part of this MD thesis, which was designed to explain the function, if any, of the anti-Epo in the pathophysiology of HIV-1-related anemia, through the detection of specific epitopes on the erythropoietin molecule, where anti-Epo are directed. Serum samples (n=32) from several HIV-1 positive patients were obtained (16 patients were anti-Epo positive and 16 were anti-Epo negative) and in addition sixteen sera from age- and sex- matched healthy blood donors were used as negative controls. Epitope mapping was conducted by the synthesis of twelve 20-mer peptides, overlapping by seven amino acids, covering the entire sequence of Epo. Sera from anti-Epo positive patients exhibited significant reactivity with the following Epo epitopes: Ep1, Ep5 and Ep12. Ep1 (1-20aa) and Ep12 (147-166aa) peptides, both exhibited significant reactivity with 13 of the 16 sera from anti-Epo positive patients, while ELISA with Ep1 and Ep12 peptides exhibited high sensitivity (81.2%) and specificity (93.7%). Furthermore, Ep5 peptide which corresponds to the 53-72 region of Epo also reacted significantly with 14/16 of the anti-Epo positive sera with high sensitivity (87.5%) and specificity (93.7%). Sera from anti-Epo patients, as well as from negative controls, exhibited no significant reactivity against any peptide. The specificity of binding of antibodies to the major epitope analogues was assessed by homologous inhibition experiments, where the reactivity of sera with Ep1, Ep5, Ep12 was inhibited by 47%, 46% and 43% respectively. In advance, the study of the Epo immunodominant regions structural characteristics, permitted us to assess that the two major antigenic epitopes, Ep1 and Ep12, located at the amino (NH2-) and the carboxy (C-) terminus of the molecule respectively, form a consecutive antigenic interface for the antibody binding. Ep1 and Ep12 comprise the interaction interface with erythropoietin receptor (EpoR). Essential precondition for the biological activity of Epo is its binding to the erythropoietin receptor, and it is likely that binding of anti-Epo to this specific region can block the Epo-EpoR interaction resulting to blunted erythropoiesis. Identification of the primary sequence of Epo epitopes allowed the use of protein databases to search sequence similarities with proteins of unrelated origin. Search results revealed that the epitope APPRLICDSRVLERYLLEAK (1-20) had 63% (12/19) similarity to a fragment (34LVCASRELERFAVNPGLLE52) of HIV-1 gag polyprotein. This amino-acid sequence corresponds to a region of p17 matrix protein (MA), which is one of the three major proteins that Gag polyprotein is consisted of. The sequence similarity observations prompted us to the construction of a new peptide (HIV1-gag) having the exact sequence with the region corresponding to matrix protein. A different peptide with the same amino-acid bases to HIV-1-gag peptide in a scrambled order (VLREFARVPENLGESLCAL) was constructed to be used as control. Both constructed peptides and Ep1 peptide were tested against selected sera from HIV-1 patients with and without anti-Epo. Experiment results showed that all sera binding to Ep1 peptide recognized the HIV-1-gag but not the p17 scrambled peptide. These results suggest that anti-Epo presence can be attributed to a molecular mimicry mechanism. Furthermore, inhibition tests were conducted with both peptides, which exhibited inhibition rates varying between 50% and 62%, results suggesting that Ep1 and HIV-1-gag peptides cross-react. Finally laboratory findings of the studied sera were examined showing significant higher Epo levels [53.63 (27.32) vs. 25.15 (9.49) ng/ml, p<0.001] and lower Hgb levels [11.8 (1.7) vs. 14 (1.4) g/dl, p<0.001] in the anti-Ep1 positive group in comparison with the anti-Ep1 negative group. In addition 9/13 (69%) of anti-Ep1 positive patients were anemic and only 4/19 (21%) of the other group (p<0.05). Noteworthy is that reactivity levels of anti-Epo positive sera are similar between Ep1 and Ep12 peptides [Spearman’s rank correlation coefficient (rs)= 0.93, p< 0.0001]. According to the above observations the significant higher serum levels of Epo, which were detected in anti-Epo positive patients sera even in the previous study, can be interpreted as a result of the blockade of the Epo-EpoR interaction leading to blunted erythropoiesis and reactive production of greater amounts of Epo. In conclusion this study demonstrates that anti-Epo autoantibodies are directed against specific linear B-cell epitopes located within the binding site of the molecule to its receptor and possess high disease sensitivity and specificity. One of the Epo epitopes (Ep1) shows molecular similarity with p-17 matrix protein of HIV-1; therefore the presence of anti-Epo in HIV-1 infected patients can be attributed to molecular mimicry mechanism.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsiakalos, Aristotelis
  • Τσιάκαλος, Αριστοτέλης

Subjects

dc:subject × 21

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/27255

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsiakalos, Aristotelis; Τσιάκαλος, Αριστοτέλης. Επιδημιολογική, κλινική, ανοσολογική, αιματολογική, θεραπευτική μελέτη Ελλήνων ασθενών με HIV-1 λοίμωξη. National and Kapodistrian University of Athens, 2011. http://hdl.handle.net/10442/hedi/27255